Gonzalo Barón-Esquivias – författare

This book presents a unique collection of clinical cases to help combat the difficulty of diagnosis and treatment of Syncope. Medical professionals using this book are provided with a reference to a large array of succinctly described and illustrated clinical scenarios. Each case is presented with the results of appropriate tests and critical comments about the evaluation, diagnosis and treatment according to guidelines.Syncope is considered a difficult diagnostic and treatment problem for all who work in the field. Regardless of your prior knowledge, you will find the case studies easy to digest, enlightening, and immediately pertinent to improving the care patients – giving you confidence in your diagnosis and your advice. The editors have developed a lively and easy-to-read book with a focused expert editorial commentary, offering the reader a broader and easily understood context for each case, as well as key citations from the literature. Syncope Cases is a valuable contribution to your collection; edited by seven prominent authorities on the management of syncope from four countries, with more than 130 contributors, this book provides a unique additional step in the fostering of a better understanding of the many factors that can cause syncope, with the ultimate goal of facilitating the delivery of more precise and cost-effective care for syncope patients. It is a contribution that should be widely read, and one that offers the possibility of distinctly enhancing medical care of the syncope patient.

This book is designed for clinical cardiologists and other physicians working with cardiac patients, where specific specialized teams of cardio-oncologists are not available and who are called to perform a clinical consultation to evaluate both the cardiac condition and the eligibility for chemotherapy or radiotherapy treatment, and to evaluate if a cancer treatment produces toxic effects on a patient treated with chemo or radiotherapy and if appearance of new symptoms is due to this treatment. In recent years, progress in oncologic therapy has resulted in important developments and the prognostic improvement of patients with malignancy. The cornerstone of chemotherapy are the anthracyclines (and the analogue Mitoxantrone), that are direct cellular toxic agents and that are among the most powerful anti-neoplastic drugs, but their cardiac toxicity is well known. Significant breakthroughs in cancer therapy have also been achieved with the introduction of signalling inhibitors, such as VEGF inhibitors, HERB2 inhibitors or TK inhibitors used alone or in combination with direct cellular toxic drugs. However, these signalling inhibitors may interact also with cardiovascular signalling and therefore may have functional or structural effects on the myocardium. This can be permanent or reversible, with impairment of the global conditions and important side effects, and increase both morbidity and mortality and worsening of quality of life. Chemotherapy and radiotherapy can have acute detrimental effects that can be present for years after treatment and that can lead to cardiac consequences also after long periods of no clinic sequelae. Patient numbers with cancer problems will dramatically increase in the next years and thus every cardiologist will need to have the correct information and the skills to manage these situations in the correct way. This book will provide these tools for them.